AUTHORS
Olisaemeka Ogbue, MBBS, Pankaj Pradeep2, Duc Tran, PhD3, Alejandro Ferrer, PhD4, Terra Lasho, PhD5, Nicholas J Boddicker, PhD6, Jenna Fernandez, Ph.D.7, Christy Finke, BS8, Madeline Ashleigh Franke, MD, MEng9, Nickolas Steinauer, M.D., Ph.D.10, Tariq Kewan, MD11, Ajoy Lawrence Dias, MD12, Abhishek Avinash Mangaonkar, MBBS13, Talha Badar, MD14, Kelly Bolton, MD, PhD15, Mrinal M. Patnaik, MD, MBBS16
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Washington University School of Medicine, St. Louis, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Washington University School of Medicine, St. Louis, United States
16 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction
Germline telomere biology disorder (TBD) variants cause inherited multisystem disease and predispose to clonal hematopoiesis (CH), hematologic malignancies (HM), and solid tumors. However, their population-level penetrance and phenotypic spectrum remain poorly defined. We used a genome-first approach to define the clinical consequences of germline TBD variants in an unascertained cohort.
Methods
We analyzed rare germline variants (MAF <0.001) in 17 established TBD genes spanning five functional modules of telomere biology: telomerase complex (TERT, DKC1, NHP2, NOP10, NAF1, WRAP53), shelterin (POT1, TINF2, ACD), CST complex (CTC1, STN1), replication/repair (RTEL1, RPA1, LIG4), and RNA processing/biogenesis (PARN, ZCCHC8, USB1) among 414,830 participants in the All of Us Research Program. Variants (missense, nonsense, splice-site, and in-/out-of-frame indels) underwent ACMG classification and inheritance-aware zygosity filtering (heterozygous for autosomal dominant, hemizygous males for X-linked recessive, and biallelic for autosomal recessive genes) to identify pathogenic/likely pathogenic (P/LP) variants and rare missense variants of uncertain significance (VUS). CH was identified across 185 driver genes (variant allele fraction ≥2%) as previously described (PMID:36652671). CH was additionally classified by lineage (myeloid and lymphoid) and driver class including DNA damage response (DDR) and signaling genes. Phenotypes were ascertained from ICD-10 codes. Associations were evaluated using Firth logistic regression adjusted for age, sex, genetic ancestry, and smoking status with false discovery rate (FDR) correction. Penetrance was estimated by cumulative incidence with competing mortality.
Results
Of 414,830 participants, 18,008 (4.3%) carried a qualifying rare TBD variant, including 1,127 (0.27%) with P/LP variants; among variant carriers, 990 (5.5%) had CH. Compared with non-carriers, individuals with any rare TBD variant had modestly increased odds of CH (OR 1.12, 95% CI 1.01–1.23), driven primarily by myeloid CH (OR 1.13, 95% CI 1.02–1.25).
Among P/LP carriers, the CH association localized to the shelterin complex genes (ACD, POT1, TINF2) (OR 1.63, 95% CI 1.12–2.29) with the strongest enrichment observed among long-telomere genes (POT1, TINF2) (OR 2.72, 95% CI 1.24–5.34). Other functional modules showed no significant association.
Gene-level analyses further refined these pathway-level findings. Although POT1 P/LP variants alone showed no independent association with CH, combined analyses of P/LP and rare missense VUS identified POT1 as the gene with the broadest CH phenotype, including overall CH (OR 1.94, 95% CI 1.37–2.67), myeloid CH (OR 2.12, 95% CI 1.48–2.95), signaling-pathway CH (JAK2, CBL, KRAS, NRAS) (OR 3.69, 95% CI 1.03–9.18), and DDR-pathway CH (TP53, PPM1D, ATM) (OR 3.01, 95% CI 1.13–6.42), all remaining significant after FDR correction (FDR-adjusted P=0.019). This observation suggests that a subset of rare POT1 missense VUS may have biological relevance for CH susceptibility
Previously unrecognized lineage-specific CH associations included LIG4 P/LP variants (n=212) with lymphoid CH (OR 16.83, 95% CI 1.89–63.17) and RPA1 P/LP variants (n=29) with DDR-pathway CH (OR 64.15, 95% CI 6.67–301.31).
Long-telomere P/LP variants preferentially predisposed to lymphoid HM, with the lymphoma association driven exclusively by POT1 (OR 2.34, 95% CI 1.03–4.51). Among solid tumors, P/LP variants were associated with thyroid cancer (OR 2.76, 95% CI 1.28–5.16) and bladder cancer (OR 2.64, 95% CI 1.16–5.08).
Despite their rarity, P/LP variants demonstrated measurable penetrance of classic TBD phenotypes. P/LP variants in RNA processing/biogenesis genes (PARN, USB1, ZCCHC8) and telomerase complex genes were independently associated with interstitial lung disease (OR 1.58, 95% CI 1.13–2.14 and OR 1.64, 95% CI 1.24–2.14, respectively). Similarly, cumulative incidence of bone marrow failure by age 50 was 2.3-fold higher among P/LP carriers than non-carriers (2.96% vs. 1.29%; P=0.035).
Conclusion
In this genome-first analysis, germline P/LP variants in TBD genes demonstrated gene- and pathway-specific associations with CH, lymphoid malignancies, select solid tumors, and classic TBD phenotypes. Long-telomere genes emerged as the principal susceptibility locus for both CH and lymphoid malignancy. CH associations across rare POT1 missense VUS support ongoing functional studies to refine variant interpretation.
DISCLOSURES
Olisaemeka Ogbue, MBBS: No relevant conflicts of interest to declare.